{"created":"2015-05-14T19:31:21+00:00","modified":"2015-05-14T19:31:21+00:00","valid":{"from":"2014-05-06T21:08:12+00:00","to":"3014-05-06T21:08:12+00:00"},"hreflang":"en","guid":"dde6b253-2035-4584-8c42-8b001ea30b23","description":"Turns out prescription drugs and over-the-counter drugs are two very different businesses.","published":"2014-05-06T21:08:12+00:00","byline":"Stacey Vanek Smith","itags":["Marketplace for Tuesday May 6, 2014","PMP:Marketplace_PMP","Marketplace","dde6b2532035584dc42c8b001ea30b23"],"tags":["APM","pharmaceuticals","Health Care","merck","prescription drugs","bayer"],"contentencoded":"<div class=\"barn-cleaned\"><p><span>If you think a licensed pharmacist is the only real difference between NyQuil and Ambien, think again. The two are the product of completely different business models.</span></p>\n<p><span>\"</span><span>Oh they’re very different,\" says Les Funtleyder, author of Healthcare Investing. \"One is bulk manufacturing, one is heavy-duty R&amp;D.\"</span><span>&nbsp;</span></p>\n<p><span>That heavy duty research and development? $5 billion.&nbsp;</span><span>That’s how much it costs to get a single prescription drug to market these days.</span></p>\n<p>Why would Merck want to focus on that business?</p>\n<p>\"The return on investment is much higher in the prescription market,\" says JB Silvers, a professor of health finance at Case Western Reserve University's Weatherhead School of Management.&nbsp;<span>He says Merck is well positioned with a strong pipeline of cancer and diabetes drugs. \"</span>If you can do well there with patented drugs that have protection against competition, you can pretty much charge what you want.\"</p>\n<p>Not so in the world of allergy pills and arch support.&nbsp;<span>The consumer drug market is all about competitive pricing and <a href=\"https://www.youtube.com/watch?v=XmCyulrusIY\" target=\"_blank\">catchy advertising</a>.&nbsp;</span></p>\n<p>\"It’s a volume market, it’s like most retail,\" says Silvers. \"You have a smaller margin, but if you sell a whole lot of it, you do really well.\"</p>\n<p>That’s what Bayer does best.&nbsp;\"<span>Bayer is going to be able to leverage their global reach to take these products to places where they haven’t been sold before,\"&nbsp;<span>says Dan Mendelson, CEO of&nbsp;</span><a href=\"http://avalerehealth.net/about-us\" target=\"_blank\">Avalere Health</a><span>.&nbsp;</span></span></p>\n<p>Mendelson says when it comes to branding, marketing and selling things like sunscreen and nasal spray, Bayer simply has a better machine.</p></div>","teaser":"Turns out prescription drugs and over-the-counter drugs are two very different businesses.","contenttemplated":"[{\"type\":\"text/html\",\"content\":\"<p><span>If you think a licensed pharmacist is the only real difference between NyQuil and Ambien, think again. The two are the product of completely different business models.</span></p>\"},{\"content\":\"<p><span>&quot;</span><span>Oh they’re very different,&quot; says Les Funtleyder, author of Healthcare Investing. &quot;One is bulk manufacturing, one is heavy-duty R&amp;D.&quot;</span><span> </span></p>\",\"type\":\"text/html\"},{\"content\":\"<p><span>That heavy duty research and development? $5 billion. </span><span>That’s how much it costs to get a single prescription drug to market these days.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p>Why would Merck want to focus on that business?</p>\",\"type\":\"text/html\"},{\"content\":\"<p>&quot;The return on investment is much higher in the prescription market,&quot; says JB Silvers, a professor of health finance at Case Western Reserve University&apos;s Weatherhead School of Management. <span>He says Merck is well positioned with a strong pipeline of cancer and diabetes drugs. &quot;</span>If you can do well there with patented drugs that have protection against competition, you can pretty much charge what you want.&quot;</p>\",\"type\":\"text/html\"},{\"content\":\"<p>Not so in the world of allergy pills and arch support. <span>The consumer drug market is all about competitive pricing and <a href=\\\"https://www.youtube.com/watch?v=XmCyulrusIY\\\" target=\\\"_blank\\\">catchy advertising</a>. </span></p>\",\"type\":\"text/html\"},{\"content\":\"<p>&quot;It’s a volume market, it’s like most retail,&quot; says Silvers. &quot;You have a smaller margin, but if you sell a whole lot of it, you do really well.&quot;</p>\",\"type\":\"text/html\"},{\"content\":\"<p>That’s what Bayer does best. &quot;<span>Bayer is going to be able to leverage their global reach to take these products to places where they haven’t been sold before,&quot; <span>says Dan Mendelson, CEO of </span><a href=\\\"http://avalerehealth.net/about-us\\\" target=\\\"_blank\\\">Avalere Health</a><span>. </span></span></p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>Mendelson says when it comes to branding, marketing and selling things like sunscreen and nasal spray, Bayer simply has a better machine.</p>\"}]","title":"Shelf vs. Script: Why Merck's offloading allergy pills","audio":[{"type":"image/jpeg","href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/56492604.jpg?itok=OxEGVtUt","meta":{"height":"340","crop":"primary","width":"610"}},{"meta":{"duration_hms":"00:02:08","duration":128,"api":{"href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2014/05/06/marketplace_segment16_20140506","type":"application/json"}},"href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2014/05/06/marketplace_segment16_20140506_64.mp3","type":"audio/mpeg","format":"MP3"}]}